<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v3.0 20080202//EN" "archivearticle3.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.0 20040830//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.0?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">09-PONE-RA-11700R1</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0007540</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline"><subject>Biochemistry</subject><subject>Cell Biology/Gene Expression</subject><subject>Genetics and Genomics/Disease Models</subject><subject>Gastroenterology and Hepatology/Hepatology</subject></subj-group></article-categories><title-group><article-title>DYRK1A, a Novel Determinant of the Methionine-Homocysteine Cycle in Different Mouse Models Overexpressing this Down-Syndrome-Associated Kinase</article-title><alt-title alt-title-type="running-head">DYRK1A and Homocysteine</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Noll</surname><given-names>Christophe</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Planque</surname><given-names>Chris</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Ripoll</surname><given-names>Cl&#x000e9;mentine</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Guedj</surname><given-names>Fay&#x000e7;al</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Diez</surname><given-names>Anna</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Ducros</surname><given-names>V&#x000e9;ronique</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Belin</surname><given-names>Nicole</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Duchon</surname><given-names>Arnaud</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Paul</surname><given-names>Jean-Louis</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><xref ref-type="aff" rid="aff5"><sup>5</sup></xref></contrib><contrib contrib-type="author"><name><surname>Badel</surname><given-names>Anne</given-names></name><xref ref-type="aff" rid="aff6"><sup>6</sup></xref></contrib><contrib contrib-type="author"><name><surname>de Freminville</surname><given-names>B&#x000e9;n&#x000e9;dicte</given-names></name><xref ref-type="aff" rid="aff7"><sup>7</sup></xref></contrib><contrib contrib-type="author"><name><surname>Grattau</surname><given-names>Yann</given-names></name><xref ref-type="aff" rid="aff8"><sup>8</sup></xref></contrib><contrib contrib-type="author"><name><surname>Bl&#x000e9;haut</surname><given-names>Henri</given-names></name><xref ref-type="aff" rid="aff9"><sup>9</sup></xref></contrib><contrib contrib-type="author"><name><surname>Herault</surname><given-names>Yann</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Janel</surname><given-names>Nathalie</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>&#x0002a;</sup></xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Delabar</surname><given-names>Jean-Maurice</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff1"><label>1</label><addr-line>University Paris Diderot-CNRS EAC 4413, Unit of Functional and Adaptive Biology (BFA), Paris, France</addr-line></aff><aff id="aff2"><label>2</label><addr-line>D&#x000e9;partement de Biologie Int&#x000e9;gr&#x000e9;e, unit&#x000e9; fonctionnelle de nutrition, CHU Grenoble, Grenoble, France</addr-line></aff><aff id="aff3"><label>3</label><addr-line>UMR6218 CNRS, Immunology and Molecular Embryology, UPS44, Institut de Transgenose, Orl&#x000e9;ans, France</addr-line></aff><aff id="aff4"><label>4</label><addr-line>AP-HP, H&#x000f4;pital Europ&#x000e9;en Georges Pompidou, Service de Biochimie, Paris, France</addr-line></aff><aff id="aff5"><label>5</label><addr-line>Universit&#x000e9; Paris-Sud, UMR 1154-INRA, Facult&#x000e9; de Pharmacie, Ch&#x000e2;tenay-Malabry, France</addr-line></aff><aff id="aff6"><label>6</label><addr-line>UMR-S 973, mol&#x000e9;cule th&#x000e9;rapeutique in silico, University Paris Diderot, Paris, France</addr-line></aff><aff id="aff7"><label>7</label><addr-line>CHU-H&#x000f4;pital Nord &#x02013; Service de G&#x000e9;n&#x000e9;tique, Saint Etienne, France</addr-line></aff><aff id="aff8"><label>8</label><addr-line>Institut J&#x000e9;r&#x000f4;me Lejeune, Paris, France</addr-line></aff><aff id="aff9"><label>9</label><addr-line>Fondation J&#x000e9;rome Lejeune, Paris, France</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Beier</surname><given-names>Frank</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">University of Western Ontario, Canada</aff><author-notes><corresp id="cor1">&#x0002a; E-mail: <email>nathalie.janel@univ-paris-diderot.fr</email></corresp><fn fn-type="con"><p>Conceived and designed the experiments: CN CP FG NJ JMD. Performed the experiments: CN CP CR FG AD NB. Analyzed the data: CN CP FG VD JLP AB NJ JMD. Contributed reagents/materials/analysis tools: AD BdF YG HB YH. Wrote the paper: NJ JMD.</p></fn></author-notes><pub-date pub-type="collection"><year>2009</year></pub-date><pub-date pub-type="epub"><day>21</day><month>10</month><year>2009</year></pub-date><volume>4</volume><issue>10</issue><elocation-id>e7540</elocation-id><history><date date-type="received"><day>17</day><month>7</month><year>2009</year></date><date date-type="accepted"><day>25</day><month>9</month><year>2009</year></date></history><permissions><copyright-statement>Noll et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</copyright-statement></permissions><abstract><sec><title>Background</title><p>Hyperhomocysteinemia, characterized by increased plasma homocysteine level, is associated with an increased risk of atherosclerosis. On the contrary, patients with Down syndrome appear to be protected from the development of atherosclerosis. We previously found a deleterious effect of hyperhomocysteinemia on expression of DYRK1A, a Down-syndrome-associated kinase. As increased expression of DYRK1A and low plasma homocysteine level have been associated with Down syndrome, we aimed to analyze the effect of its over-expression on homocysteine metabolism in mice.</p></sec><sec><title>Methodology/Principal Findings</title><p>Effects of DYRK1A over-expression were examined by biochemical analysis of methionine metabolites, real-time quantitative reverse-transcription polymerase chain reaction, and enzyme activities. We found that over-expression of Dyrk1a increased the hepatic NAD(P)H:quinone oxidoreductase and S-adenosylhomocysteine hydrolase activities, concomitant with decreased level of plasma homocysteine in three mice models overexpressing Dyrk1a. Moreover, these effects were abolished by treatment with harmine, the most potent and specific inhibitor of Dyrk1a. The increased NAD(P)H:quinone oxidoreductase and S-adenosylhomocysteine hydrolase activities were also found in lymphoblastoid cell lines from patients with Down syndrome.</p></sec><sec><title>Conclusions/Significance</title><p>Our results might give clues to understand the protective effect of Down syndrome against vascular defect through a decrease of homocysteine level by DYRK1A over-expression. They reveal a link between the Dyrk1a signaling pathway and the homocysteine cycle.</p></sec></abstract><counts><page-count count="11"/></counts></article-meta></front><body><sec id="s1"><title>Introduction</title><p>Homocysteine (Hcy) is a sulfur-containing amino acid formed during the intracellular conversion of methionine via the adenosylated compounds S-adenosylmethionine (SAM) and S-adenosylhomocysteine (SAH). The formation of SAM is catabolized by methionine adenosyl transferase (MAT). Once Hcy is formed, it may be recycled to methionine after remethylation by two different pathways. The first one involves methionine synthase (MS), an enzyme that uses vitamin B<sub>12</sub> (cobalamin) as an essential cofactor and 5-methyltetrahydrofolate as the methyl donor. The 5-methyltetrahydrofolate is generated by 5, 10-methylene tetrahydrofolate reductase (MTHFR) <xref ref-type="bibr" rid="pone.0007540-Selhub1">&#x0005b;1&#x0005d;</xref>. The second pathway, which occurs in liver and kidney, involves the enzyme betaine-homocysteine methyltransferase (BHMT). Hcy may also undergo condensation with serine to form cystathionine, which is catalyzed by the vitamin B<sub>6</sub>-dependent enzyme cystathionine beta synthase (CBS), the first enzyme involved in the transsulfuration pathway. Cystathionine is subsequently hydrolysed to form cysteine which can be, in turn, incorporated into protein or used to synthesize the antioxidant glutathione. Hcy can also turn back to SAH via reversal of the SAH hydrolase (SAHH) reaction <xref ref-type="bibr" rid="pone.0007540-Selhub1">&#x0005b;1&#x0005d;</xref>.</p><p>Elevated plasma Hcy levels are well-recognized as an independant risk factor for atherosclerosis in the coronary, cerebrovascular and peripheral arterial circulation <xref ref-type="bibr" rid="pone.0007540-Welch1">&#x0005b;2&#x0005d;</xref>. Conversely, although Down syndrome (DS) is associated with a great variety of phenotypes, the incidence of atherosclerotic vascular disease seems to be low <xref ref-type="bibr" rid="pone.0007540-Murdoch1">&#x0005b;3&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007540-Draheim1">&#x0005b;4&#x0005d;</xref>. Even if the coronary arteries of DS patients were not completely free of atherosclerosis, it was milder than in other mentally retarded patients and in control subjects of the same age <xref ref-type="bibr" rid="pone.0007540-YlaHerttuala1">&#x0005b;5&#x0005d;</xref>. Moreover, healthy old DS patients showed some classical biochemical risk factors for atherosclerosis but did not suffer from clinical cardiovascular alterations <xref ref-type="bibr" rid="pone.0007540-Licastro1">&#x0005b;6&#x0005d;</xref>. Because many genetic factors can be related to this reduction, the reasons for this apparent protection against atherosclerosis remain unclear. DYRK1A, which gene is localized on human chromosome 21, is a protein kinase that belongs to an evolutionarily conserved family of proteins known as DYRKs (dual-specificity tyrosine-(Y)-phosphorylation regulated kinase) involved in diverse functions ranging from development, growth to apoptosis <xref ref-type="bibr" rid="pone.0007540-Becker1">&#x0005b;7&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0007540-Laguna1">&#x0005b;9&#x0005d;</xref>. On the one hand, we recently reported a reduction of Dyrk1a protein level in liver of CBS-deficient mice, a murine model of hyperhomocysteinemia <xref ref-type="bibr" rid="pone.0007540-Hamelet1">&#x0005b;10&#x0005d;</xref>, suggesting a link between DYRK1A related pathways and the Hcy cycle. On the other hand, an increased expression of DYRK1A and low plasma Hcy levels have been associated with DS <xref ref-type="bibr" rid="pone.0007540-Licastro1">&#x0005b;6&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007540-Pogribna1">&#x0005b;11&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0007540-Galletti1">&#x0005b;13&#x0005d;</xref>. To analyze further the relation between DYRK1A and Hcy metabolism, we used four transgenic models to demonstrate the effect of the over-expression of Dyrk1a on Hcy metabolism: a model of hyperhomocysteinemia due to CBS deficiency <xref ref-type="bibr" rid="pone.0007540-Watanabe1">&#x0005b;14&#x0005d;</xref> and three models with duplications of increasing complexity and over-expression of Dyrk1a <xref ref-type="bibr" rid="pone.0007540-Smith1">&#x0005b;15&#x0005d;</xref>: a BAC transgenic with one copy of the murine Dyrk1a gene; a YAC transgenic for a human chromosome 21 fragment carrying five genes including DYRK1A; a partial trisomy 16 mouse carrying an extra copy of a region of MMU16 syntenic for a region of HSA21 between Mrpl39 and Znf295 containing 138 genes (also including Dyrk1a) and considered to be a valid mouse model of human Down syndrome <xref ref-type="bibr" rid="pone.0007540-Davisson1">&#x0005b;16&#x0005d;</xref>.</p></sec><sec id="s2"><title>Results</title><sec id="s2a"><title>DYRK1A over-expression reduces the plasma Hcy levels in mice</title><p>In order to analyze the over-expression of DYRK1A on plasma Hcy levels, we used three models of mice, which overexpress not only the murine gene, but also the human one. The transgenic line (Tg) 152F7 contains five human genes including DYRK1A. The Tg 189N3 contains the murine orthologue of DYRK1A. The Ts65Dn line is the most complete of the commonly available mouse models of the mouse partial trisomy 16 and exhibits morphological and biochemical changes seen in DS <xref ref-type="bibr" rid="pone.0007540-Davisson2">&#x0005b;17&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007540-Holtzman1">&#x0005b;18&#x0005d;</xref>. We first analyzed the overexpression of DYRK1A in liver of mice. Male Tg 152F7 mice, two months of age, showed a two-fold increase in gene expression of DYRK1A in the liver compared to non-transgenic mice (<xref ref-type="fig" rid="pone-0007540-g001">Fig. 1A</xref>). Female Tg 189N3 mice, two months of age, showed a 1.4-fold increase in gene expression of <italic>Dyrk1a</italic> compared to non-transgenic mice (<xref ref-type="fig" rid="pone-0007540-g001">Fig. 1B</xref>). Male Ts65Dn mice, six months of age, showed a 1.6-fold increase in gene expression of <italic>Dyrk1a</italic> compared to non-transgenic mice (<xref ref-type="fig" rid="pone-0007540-g001">Fig. 1D</xref>). Commensurate with the mRNA expression, protein expression of DYRK1A was 1.3 fold, 1.6 fold and 1.7 fold higher in liver of Tg 152F7, Tg 189N3, and Ts65Dn mice respectively (<xref ref-type="fig" rid="pone-0007540-g002">Fig. 2</xref> and <xref ref-type="fig" rid="pone-0007540-g001">Figs. 1C, 1E</xref>).</p><fig id="pone-0007540-g001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0007540.g001</object-id><label>Figure 1</label><caption><title>Hepatic DYRK1A mRNA and protein expression in liver of transgenic mice.</title><p>Relative expression of DYRK1A gene was based on Q-PCR data and protein expression was determined by normalization of the density of images from DYRK1A with that of &#x003b2;-actin of the same blot. The values of Tg 152F7, Tg189N3 and Ts65Dn were normalized to the mean Tg &#x02013; mice from each lines. The blots are representative of three independent experiments. Data correspond to means &#x000b1; SEM and the statistical analysis was done by Student's unpaired <italic>t</italic>-tests. n&#x0200a;&#x0003d;&#x0200a;number of mice.</p></caption><graphic xlink:href="pone.0007540.g001"/></fig><fig id="pone-0007540-g002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0007540.g002</object-id><label>Figure 2</label><caption><title>DYRK1A protein expression in liver of CBS-deficient mice crossbred with 152F7 transgenic mice.</title><p>(A) Western immunoblots showing DYRK1A expression in liver of wild type mice (<italic>Cbs</italic><sup>&#x0002b;/&#x0002b;</sup> Tg -), heterozygous mice (<italic>Cbs</italic><sup>&#x0002b;/&#x02212;</sup> Tg -), 152F7 transgenic mice (<italic>Cbs</italic><sup>&#x0002b;/&#x0002b;</sup> Tg 152F7), and heterozygous mice crossbred with 152F7 transgenic mice (<italic>Cbs</italic><sup>&#x0002b;/&#x02212;</sup> Tg 152F7). Proteins were subjected to immunoblot analysis using antibodies specific to DYRK1A (85.5 kDa). After stripping, the membranes were reprobed with anti-&#x003b2;-actin antibody (41.7 kDa) for the control. (B) Relative protein expression was determined by normalization of the density of images from DYRK1A with that of &#x003b2;-actin of the same blot. The values of <italic>Cbs</italic><sup>&#x0002b;/&#x02212;</sup> Tg -, <italic>Cbs</italic><sup>&#x0002b;/&#x0002b;</sup> Tg 152F7, or <italic>Cbs</italic><sup>&#x0002b;/&#x02212;</sup> Tg 152F7 were normalized to the mean of <italic>Cbs</italic><sup>&#x0002b;/&#x0002b;</sup> Tg - mice. The blots are representative of three independent experiments. Data correspond to means &#x000b1; SEM and the statistical analysis was done with one-way ANOVA followed by Student's unpaired <italic>t</italic>-tests. n&#x0200a;&#x0003d;&#x0200a;number of mice.</p></caption><graphic xlink:href="pone.0007540.g002"/></fig><p>In order to show the effect of over-expression of DYRK1A on plasma Hcy level, serum of Tg 152F7 and heterozygous CBS-deficient (<italic>Cbs</italic><sup>&#x0002b;/&#x02212;</sup>) mice crossbred with Tg 152F7 mice was analyzed by HPLC. Tg 152F7 mice (<italic>Cbs</italic><sup>&#x0002b;/&#x0002b;</sup> Tg 152F7; <xref ref-type="fig" rid="pone-0007540-g003">Fig. 3A</xref> and <xref ref-type="table" rid="pone-0007540-t001">Table 1</xref>) have a Hcy level 1.4-fold lower than those of <italic>Cbs</italic><sup>&#x0002b;/&#x0002b;</sup> mice (<italic>Cbs</italic><sup>&#x0002b;/&#x0002b;</sup> Tg -; <xref ref-type="fig" rid="pone-0007540-g003">Fig. 3A</xref> and <xref ref-type="table" rid="pone-0007540-t001">Table 1</xref>). As previously shown <xref ref-type="bibr" rid="pone.0007540-Hamelet1">&#x0005b;10&#x0005d;</xref>, Dyrk1a protein expression was decreased in liver of <italic>Cbs</italic><sup>&#x0002b;/&#x02212;</sup> mice (<italic>Cbs</italic><sup>&#x0002b;/&#x02212;</sup> Tg -; <xref ref-type="fig" rid="pone-0007540-g002">Fig. 2</xref>), compared with protein extracted from <italic>Cbs</italic><sup>&#x0002b;/&#x0002b;</sup> mice (<italic>Cbs</italic><sup>&#x0002b;/&#x0002b;</sup> Tg -; <xref ref-type="fig" rid="pone-0007540-g002">Fig. 2</xref>). <italic>Cbs</italic><sup>&#x0002b;/&#x02212;</sup> mice crossbred with Tg 152F7 mice (<italic>Cbs</italic><sup>&#x0002b;/&#x02212;</sup> Tg 152F7; <xref ref-type="fig" rid="pone-0007540-g002">Fig. 2</xref>) also showed a 1.3 fold-increased hepatic expression of DYRK1A compared to <italic>Cbs</italic><sup>&#x0002b;/&#x02212;</sup> mice (<italic>Cbs</italic><sup>&#x0002b;/&#x02212;</sup> Tg -; <xref ref-type="fig" rid="pone-0007540-g002">Fig. 2</xref>). As expected, Hcy level of <italic>Cbs</italic><sup>&#x0002b;/&#x02212;</sup> mice (<italic>Cbs</italic><sup>&#x0002b;/&#x02212;</sup> Tg -; <xref ref-type="fig" rid="pone-0007540-g003">Fig. 3A</xref>) was 1.7-fold higher than those of <italic>Cbs</italic><sup>&#x0002b;/&#x0002b;</sup> mice (<italic>Cbs</italic><sup>&#x0002b;/&#x0002b;</sup> Tg -; <xref ref-type="fig" rid="pone-0007540-g003">Fig. 3A</xref>). However, <italic>Cbs</italic><sup>&#x0002b;/&#x02212;</sup> mice crossbred with Tg 152F7 mice (<italic>Cbs</italic><sup>&#x0002b;/&#x02212;</sup> Tg 152F7; <xref ref-type="fig" rid="pone-0007540-g003">Fig. 3A</xref>) have a Hcy level 1.4-fold lower than those of <italic>Cbs</italic><sup>&#x0002b;/&#x02212;</sup> mice (<italic>Cbs</italic><sup>&#x0002b;/&#x02212;</sup> Tg -; <xref ref-type="fig" rid="pone-0007540-g003">Fig. 3A</xref>). Tg 189N3 and Ts65Dn mice have also a Hcy level 2.35-fold and 1.4-fold lower than those of non-transgenic mice respectively (<xref ref-type="table" rid="pone-0007540-t001">Table 1</xref>). These results emphasize the effect of over-expression of DYRK1A on plasma Hcy level, not only in case of hyperhomocysteinemia but also in the context of DS.</p><fig id="pone-0007540-g003" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0007540.g003</object-id><label>Figure 3</label><caption><title>Plasma Hcy level is decreased in 152F7 transgenic mice and in CBS-deficient mice crossbred with 152F7 transgenic mice.</title><p>(A) Plasma Hcy level, (B) hepatic CBS, (C) SAHH and (D) NQO1 activity in wild type mice (<italic>Cbs</italic><sup>&#x0002b;/&#x0002b;</sup> Tg -), heterozygous mice (<italic>Cbs</italic><sup>&#x0002b;/&#x02212;</sup> Tg -), 152F7 transgenic mice (<italic>Cbs</italic><sup>&#x0002b;/&#x0002b;</sup> Tg 152F7), and heterozygous mice crossbred with 152F7 transgenic mice (<italic>Cbs</italic><sup>&#x0002b;/&#x02212;</sup> Tg 152F7). The values were normalized to the mean of <italic>Cbs</italic><sup>&#x0002b;/&#x0002b;</sup> Tg - mice. Data correspond to means &#x000b1; SEM and the statistical analysis was done with one-way ANOVA followed by Student's unpaired <italic>t</italic>-tests. n&#x0200a;&#x0003d;&#x0200a;number of mice.</p></caption><graphic xlink:href="pone.0007540.g003"/></fig><table-wrap id="pone-0007540-t001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0007540.t001</object-id><label>Table 1</label><caption><title>Plasma Hcy levels, hepatic SAM and SAH concentrations, and hepatic SAM/SAH ratio in transgenic mice.</title></caption><alternatives><graphic id="pone-0007540-t001-1" xlink:href="pone.0007540.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Genotype (n&#x0200a;&#x0003d;&#x0200a;number of mice)</td><td align="left" rowspan="1" colspan="1">Hcy (&#x000b5;M)</td><td align="left" rowspan="1" colspan="1">SAM (nmol/g)</td><td align="left" rowspan="1" colspan="1">SAH (nmol/g)</td><td align="left" rowspan="1" colspan="1">SAM/SAH</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Tg &#x02013; (n&#x0200a;&#x0003d;&#x0200a;4)</td><td align="left" rowspan="1" colspan="1">3.9&#x000b1;0.3</td><td align="left" rowspan="1" colspan="1">79.5&#x000b1;9.1</td><td align="left" rowspan="1" colspan="1">52.7&#x000b1;3.1</td><td align="left" rowspan="1" colspan="1">1.5&#x000b1;0.2</td></tr><tr><td align="left" rowspan="1" colspan="1">Tg 152F7 (n&#x0200a;&#x0003d;&#x0200a;6)</td><td align="left" rowspan="1" colspan="1">2.9&#x000b1;0.2&#x0002a;</td><td align="left" rowspan="1" colspan="1">73.2&#x000b1;6.4</td><td align="left" rowspan="1" colspan="1">42.4&#x000b1;4.1</td><td align="left" rowspan="1" colspan="1">1.8&#x000b1;0.2</td></tr><tr><td align="left" rowspan="1" colspan="1">Tg &#x02013; (n&#x0200a;&#x0003d;&#x0200a;5)</td><td align="left" rowspan="1" colspan="1">4.7&#x000b1;0.6</td><td align="left" rowspan="1" colspan="1">64.8&#x000b1;10.3</td><td align="left" rowspan="1" colspan="1">35.7&#x000b1;3.3</td><td align="left" rowspan="1" colspan="1">1.8&#x000b1;0.2</td></tr><tr><td align="left" rowspan="1" colspan="1">Tg 189N3 (n&#x0200a;&#x0003d;&#x0200a;5)</td><td align="left" rowspan="1" colspan="1">2&#x000b1;0.1<bold><sup>&#x02021;</sup></bold></td><td align="left" rowspan="1" colspan="1">67.7 &#x000b1;6.5</td><td align="left" rowspan="1" colspan="1">35.5&#x000b1;3.1</td><td align="left" rowspan="1" colspan="1">2&#x000b1;0.2</td></tr><tr><td align="left" rowspan="1" colspan="1">Tg &#x02013; (n&#x0200a;&#x0003d;&#x0200a;7)</td><td align="left" rowspan="1" colspan="1">2.6&#x000b1;0.1</td><td align="left" rowspan="1" colspan="1">52&#x000b1;3.8</td><td align="left" rowspan="1" colspan="1">44&#x000b1;3.1</td><td align="left" rowspan="1" colspan="1">1.2&#x000b1;0.1</td></tr><tr><td align="left" rowspan="1" colspan="1">Ts65Dn (n&#x0200a;&#x0003d;&#x0200a;6)</td><td align="left" rowspan="1" colspan="1">1.9&#x000b1;0.3&#x0002a;</td><td align="left" rowspan="1" colspan="1">35.6&#x000b1;3.5<bold><sup>&#x02020;</sup></bold></td><td align="left" rowspan="1" colspan="1">51.4&#x000b1;3.8</td><td align="left" rowspan="1" colspan="1">0.7&#x000b1;0.1<bold><sup>&#x02020;</sup></bold></td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt101"><label/><p>Data correspond to means &#x000b1; SEM and the statistical analysis was done by Student's unpaired <italic>t</italic>-tests. &#x0002a; <italic>p</italic>&#x0003c;0.04; <bold><sup>&#x02020;</sup></bold><italic>p</italic>&#x0003c;0.01; <bold><sup>&#x02021;</sup></bold><italic>p</italic>&#x0003c;0.002.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s2b"><title>DYRK1A over-expression modulates SAHH activity</title><p>As CBS is a key enzyme of Hcy metabolism <xref ref-type="bibr" rid="pone.0007540-Finkelstein1">&#x0005b;19&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007540-Stead1">&#x0005b;20&#x0005d;</xref>, we first assayed the CBS activity in liver samples of mice. As expected, <italic>Cbs</italic><sup>&#x0002b;/&#x02212;</sup> mice (<italic>Cbs</italic><sup>&#x0002b;/&#x02212;</sup> Tg -; <xref ref-type="fig" rid="pone-0007540-g003">Fig. 3B</xref>) showed a significant decrease of CBS activity when compared with <italic>Cbs</italic><sup>&#x0002b;/&#x0002b;</sup> mice (<italic>Cbs</italic><sup>&#x0002b;/&#x0002b;</sup> Tg -; <xref ref-type="fig" rid="pone-0007540-g003">Fig. 3B</xref>). Tg 152F7 mice (<italic>Cbs</italic><sup>&#x0002b;/&#x0002b;</sup> Tg 152F7; <xref ref-type="fig" rid="pone-0007540-g003">Fig. 3B</xref>) have the same CBS activity than that of <italic>Cbs</italic><sup>&#x0002b;/&#x0002b;</sup> mice (<italic>Cbs</italic><sup>&#x0002b;/&#x0002b;</sup> Tg -; <xref ref-type="fig" rid="pone-0007540-g003">Fig. 3B</xref>). However, <italic>Cbs</italic><sup>&#x0002b;/&#x02212;</sup> mice crossbred with Tg 152F7 mice (<italic>Cbs</italic><sup>&#x0002b;/&#x02212;</sup> Tg 152F7; <xref ref-type="fig" rid="pone-0007540-g003">Fig. 3B</xref>) showed a decrease of CBS activity like <italic>Cbs</italic><sup>&#x0002b;/&#x02212;</sup> mice when compared with <italic>Cbs</italic><sup>&#x0002b;/&#x0002b;</sup> mice. Tg 189N3 (110&#x000b1;4 <italic>versus</italic> 100&#x000b1;7; <italic>p</italic>&#x0003c;0.26 by Student's <italic>t</italic> test <italic>n</italic>&#x0200a;&#x0003d;&#x0200a;5 for each) and Ts65Dn (111&#x000b1;7 <italic>versus</italic> 100&#x000b1;3; <italic>p</italic>&#x0003c;0.17 by Student's <italic>t</italic> test <italic>n</italic>&#x0200a;&#x0003d;&#x0200a;5 for each) mice have also the same CBS activity than that of non-transgenic mice. Then our results show that dyrk1a overexpression has no effect on CBS activity.</p><p>As Hcy can revert back to SAH via the SAHH mediated reverse reaction, we assayed SAHH activity in mouse liver. Tg 152F7 mice (<italic>Cbs</italic><sup>&#x0002b;/&#x0002b;</sup> Tg 152F7; <xref ref-type="fig" rid="pone-0007540-g003">Fig. 3C</xref>) showed an increase of SAHH activity when compared with <italic>Cbs</italic><sup>&#x0002b;/&#x0002b;</sup> mice (<italic>Cbs</italic><sup>&#x0002b;/&#x0002b;</sup> Tg -; <xref ref-type="fig" rid="pone-0007540-g003">Fig. 3C</xref>). Moreover, <italic>Cbs</italic><sup>&#x0002b;/&#x02212;</sup> mice crossbred with Tg 152F7 mice (<italic>Cbs</italic><sup>&#x0002b;/&#x02212;</sup> Tg 152F7; <xref ref-type="fig" rid="pone-0007540-g003">Fig. 3C</xref>) counteracted the decreased SAHH activity when compared with <italic>Cbs</italic><sup>&#x0002b;/&#x02212;</sup> mice (<italic>Cbs</italic><sup>&#x0002b;/&#x02212;</sup> Tg -; <xref ref-type="fig" rid="pone-0007540-g003">Fig. 3C</xref>). Tg 189N3 (<xref ref-type="fig" rid="pone-0007540-g004">Fig. 4A</xref>) and Ts65Dn (<xref ref-type="fig" rid="pone-0007540-g004">Fig. 4B</xref>) mice also showed an increased SAHH activity when compared to non-transgenic mice. We also determined the hepatic levels of SAM and SAH in Tg mice overexpressing DYRK1A and found that levels of SAM and SAH in liver of Tg 152F7 and Tg189N3 did not differ from non-transgenic mice (<xref ref-type="table" rid="pone-0007540-t001">Table 1</xref>). However, we found a decreased level of SAM in liver of Ts65Dn mice compared to non-transgenic mice, leading to decreased SAM to SAH ratio (<xref ref-type="table" rid="pone-0007540-t001">Table 1</xref>).</p><fig id="pone-0007540-g004" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0007540.g004</object-id><label>Figure 4</label><caption><title>Hepatic SAHH activity is increased in Tg 189N3 and Ts65Dn transgenic mice.</title><p>SAHH activity in (A) Tg 189N3 and (B) Ts65Dn transgenic mice. The values were normalized to the mean of Tg &#x02013; mice from each line. Data correspond to means &#x000b1; SEM and the statistical analysis was done by Student's unpaired <italic>t</italic>-test. n&#x0200a;&#x0003d;&#x0200a;number of mice.</p></caption><graphic xlink:href="pone.0007540.g004"/></fig><p>In order to determine if other enzymes of the methionine and folate cycles are altered, we assayed the mRNA expression of the major enzymes involved in the metabolism of Hcy in the liver of Tg 189N3. We found that even if the <italic>Mat1a</italic> mRNA expression was not affected in Tg 189N3 mice (data not shown), the <italic>Bhmt</italic>, <italic>Ms</italic> and <italic>Mthfr</italic> mRNA expression were increased compared to non-transgenic mice (<xref ref-type="table" rid="pone-0007540-t002">Table 2</xref>). However, the <italic>Sahh</italic> mRNA expression was decreased in Tg 189N3 mice compared to non-transgenic mice (<xref ref-type="table" rid="pone-0007540-t002">Table 2</xref>).</p><table-wrap id="pone-0007540-t002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0007540.t002</object-id><label>Table 2</label><caption><title>Relative expression of SAHH, BHMT, MS and MTHFR gene based upon Q-PCR data obtained from non-transgenic and Tg189N3 mice.</title></caption><alternatives><graphic id="pone-0007540-t002-2" xlink:href="pone.0007540.t002"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Genotype (n&#x0200a;&#x0003d;&#x0200a;number of mice)</td><td align="left" rowspan="1" colspan="1">SAHH (&#x00025; of control)</td><td align="left" rowspan="1" colspan="1">BHMT (&#x00025; of control)</td><td align="left" rowspan="1" colspan="1">MS (&#x00025; of control)</td><td align="left" rowspan="1" colspan="1">MTHFR (&#x00025; of control)</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Tg &#x02013; (n&#x0200a;&#x0003d;&#x0200a;4)</td><td align="left" rowspan="1" colspan="1">104&#x000b1;14</td><td align="left" rowspan="1" colspan="1">100&#x000b1;6</td><td align="left" rowspan="1" colspan="1">100&#x000b1;4</td><td align="left" rowspan="1" colspan="1">103&#x000b1;11</td></tr><tr><td align="left" rowspan="1" colspan="1">Tg 189N3 (n&#x0200a;&#x0003d;&#x0200a;4)</td><td align="left" rowspan="1" colspan="1">55&#x000b1;12<bold><sup>&#x02020;</sup></bold></td><td align="left" rowspan="1" colspan="1">242&#x000b1;45<bold><sup>&#x02020;</sup></bold></td><td align="left" rowspan="1" colspan="1">891&#x000b1;195<bold><sup>&#x02020;</sup></bold></td><td align="left" rowspan="1" colspan="1">726&#x000b1;330&#x0002a;</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt102"><label/><p>The values of Tg189N3 were normalized to the mean Tg &#x02013; mice. Data correspond to means &#x000b1; SEM and the statistical analysis was done by Student's unpaired <italic>t</italic>-tests. n&#x0200a;&#x0003d;&#x0200a;number of mice. &#x0002a;<italic>p</italic>&#x0200a;&#x0003d;&#x0200a;0.068; <bold><sup>&#x02020;</sup></bold><italic>p</italic>&#x0003c; 0.03.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s2c"><title>Plasma Hcy level is negatively correlated with hepatic DYRK1A expression and SAHH activity</title><p>We previously observed a negative correlation between plasma Hcy levels and hepatic DYRK1A expression, which emphasizes the effect of hyperhomocysteinemia on DYRK1A expression <xref ref-type="bibr" rid="pone.0007540-Hamelet1">&#x0005b;10&#x0005d;</xref>. Then we investigated if there are any links between Hcy concentration, hepatic DYRK1A protein expression and hepatic SAHH activity. We observed a significant negative correlation between plasma Hcy level and not only hepatic DYRK1A protein expression (&#x003c1;&#x0200a;&#x0003d;&#x0200a;&#x02212;0.48, p&#x0003c;0.04; <xref ref-type="fig" rid="pone-0007540-g005">Fig. 5A</xref>) but also hepatic SAHH activity (&#x003c1;&#x0200a;&#x0003d;&#x0200a;&#x02212;0.61, p&#x0003c;0.006; <xref ref-type="fig" rid="pone-0007540-g005">Fig. 5B</xref>). Moreover, hepatic DYRK1A protein expression was also positively correlated with hepatic SAHH activity (&#x003c1;&#x0200a;&#x0003d;&#x0200a;0.47, p&#x0003c;0.05; <xref ref-type="fig" rid="pone-0007540-g005">Fig. 5C</xref>). Multivariate analysis revealed a negative correlation between plasma Hcy level and hepatic DYRK1A protein expression and SAHH activity (<xref ref-type="fig" rid="pone-0007540-g005">Fig. 5D</xref>), indicating that high Hcy levels are associated with low hepatic DYRK1A protein expression and low hepatic SAHH activity in mice.</p><fig id="pone-0007540-g005" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0007540.g005</object-id><label>Figure 5</label><caption><title>Plasma Hcy level, DYRK1A protein expression and SAHH activity are correlated.</title><p>Hepatic DYRK1A expression and SAHH activity are presented as percent of <italic>Cbs</italic><sup>&#x0002b;/&#x0002b;</sup> Tg &#x02013; mice. Correlation of plasma Hcy level vs. (A) hepatic DYRK1A protein expression or (B) hepatic SAHH activity. Increasing levels of plasma Hcy and hepatic DYRK1A protein expression or SAHH activity are negatively correlated at <italic>p</italic>&#x0003c;0.04 and <italic>p</italic>&#x0003c;0.006 with a &#x003c1;&#x0200a;&#x0003d;&#x0200a;&#x02212;0.48 and &#x003c1;&#x0200a;&#x0003d;&#x0200a;&#x02212;0.61 respectively. Correlation of hepatic DYRK1A protein expression vs. SAHH activity (C). Increasing levels of hepatic DYRK1A protein expression and hepatic SAHH activity are positively correlated at <italic>p</italic>&#x0003c;0.05 with a &#x003c1;&#x0200a;&#x0003d;&#x0200a;0.47. (D) Graph of PCA. The three quantitative variables corresponding of plasma Hcy level, hepatic DYRK1A protein expression and hepatic SAHH activity are represented by vectors.</p></caption><graphic xlink:href="pone.0007540.g005"/></fig></sec><sec id="s2d"><title>DYRK1A over-expression modulates NQO1 activity</title><p>We found that the <italic>Sahh</italic> mRNA expression not only was decreased in Tg 189N3 mice (<xref ref-type="table" rid="pone-0007540-t002">Table 2</xref>) but also in Ts65Dn (69.6&#x000b1;5.6 <italic>versus</italic> 102.1&#x000b1;8.5; <italic>p</italic>&#x0003c;0.005 by Student's <italic>t</italic> test <italic>n</italic>&#x0200a;&#x0003d;&#x0200a;4 for each mouse) compared to non-transgenic mice. The increased activity of NAD(P)H:quinone oxidoreductase (NQO1) is followed by an increase of a by-product of the enzyme reaction, NAD&#x0002b;, which is a cofactor of SAHH <xref ref-type="bibr" rid="pone.0007540-Hershfield1">&#x0005b;21&#x0005d;</xref>. In order to determine if SAHH is a direct or an indirect target of Dyrk1a, we analyzed the activity of NQO1 in liver of transgenic mice. We found an increased activity of NQO1 not only in Tg152F7 (<italic>Cbs</italic><sup>&#x0002b;/&#x0002b;</sup> Tg 152F7; <xref ref-type="fig" rid="pone-0007540-g003">Fig. 3D</xref>), Tg 189N3 but also in Ts65Dn mice compared to non-transgenic mice (<xref ref-type="fig" rid="pone-0007540-g003">Fig. 3D</xref> and <xref ref-type="table" rid="pone-0007540-t003">Table 3</xref>). Moreover, <italic>Cbs</italic><sup>&#x0002b;/&#x02212;</sup> mice crossbred with Tg 152F7 mice (<italic>Cbs</italic><sup>&#x0002b;/&#x02212;</sup> Tg 152F7; <xref ref-type="fig" rid="pone-0007540-g003">Fig. 3D</xref>) counteracted the decreased NQO1 activity when compared with <italic>Cbs</italic><sup>&#x0002b;/&#x02212;</sup> mice (<italic>Cbs</italic><sup>&#x0002b;/&#x02212;</sup> Tg -; <xref ref-type="fig" rid="pone-0007540-g003">Fig. 3D</xref>). Commensurate with the increased activity, mRNA expression of NQO1 was 1.8 fold higher in liver of Tg 189N3 and Ts65Dn mice compared to non-transgenic mice (<xref ref-type="table" rid="pone-0007540-t003">Table 3</xref>).</p><table-wrap id="pone-0007540-t003" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0007540.t003</object-id><label>Table 3</label><caption><title>Relative expression of NQO1 gene based upon Q-PCR data and NQO1 activity obtained from non-transgenic and Tg189N3 and Ts65Dn mice.</title></caption><alternatives><graphic id="pone-0007540-t003-3" xlink:href="pone.0007540.t003"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Genotype (n&#x0200a;&#x0003d;&#x0200a;number of mice)</td><td align="left" rowspan="1" colspan="1">mRNA expression (&#x00025; of control)</td><td align="left" rowspan="1" colspan="1">activity (&#x00025; of control)</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Tg -</td><td align="left" rowspan="1" colspan="1">100.7&#x000b1;4 (n&#x0200a;&#x0003d;&#x0200a;4)</td><td align="left" rowspan="1" colspan="1">100&#x000b1;20,9 (n&#x0200a;&#x0003d;&#x0200a;3)</td></tr><tr><td align="left" rowspan="1" colspan="1">Tg 189N3</td><td align="left" rowspan="1" colspan="1">177.3&#x000b1;37.3&#x0002a; (n&#x0200a;&#x0003d;&#x0200a;3)</td><td align="left" rowspan="1" colspan="1">379.5 &#x000b1;74.2&#x0002a; (n&#x0200a;&#x0003d;&#x0200a;4)</td></tr><tr><td align="left" rowspan="1" colspan="1">Tg &#x02013;</td><td align="left" rowspan="1" colspan="1">100.9&#x000b1;5 (n&#x0200a;&#x0003d;&#x0200a;4)</td><td align="left" rowspan="1" colspan="1">100&#x000b1;27,2 (n&#x0200a;&#x0003d;&#x0200a;5)</td></tr><tr><td align="left" rowspan="1" colspan="1">Ts65Dn</td><td align="left" rowspan="1" colspan="1">176.3&#x000b1;22.6<bold><sup>&#x02020;</sup></bold> (n&#x0200a;&#x0003d;&#x0200a;4)</td><td align="left" rowspan="1" colspan="1">212&#x000b1;32,5&#x0002a; (n&#x0200a;&#x0003d;&#x0200a;5)</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt103"><label/><p>The values of Tg189N3 and Ts65Dn were normalized to the mean Tg &#x02013; mice from each line. Data correspond to means &#x000b1; SEM and the statistical analysis was done by Student's unpaired <italic>t</italic>-tests. n&#x0200a;&#x0003d;&#x0200a;number of mice. &#x0002a;<italic>p</italic>&#x0003c;0.03; <bold><sup>&#x02020;</sup></bold><italic>p</italic>&#x0003c;0.01.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s2e"><title>Harmine inhibits the effects of DYRK1A over-expression on SAHH activity</title><p>In order to determine if the effects are dependent on Dyrk1a kinase activity, we treated Tg 189N3 mice with harmine, the most potent and specific inhibitor of Dyrk1a <xref ref-type="bibr" rid="pone.0007540-Bain1">&#x0005b;22&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007540-Kuhn1">&#x0005b;23&#x0005d;</xref>. Even non-transgenic mice treated with harmine (Tg &#x02013; Harmine, <xref ref-type="fig" rid="pone-0007540-g006">Fig. 6A</xref>) showed an increased SAHH activity compared to untreated non-transgenic mice (Tg &#x02013; Vehicle, <xref ref-type="fig" rid="pone-0007540-g006">Fig. 6A</xref>), Tg 189N3 mice treated with harmine (Tg 189N3 Harmine, <xref ref-type="fig" rid="pone-0007540-g006">Fig. 6A</xref>) had the same increased activity than that of non-transgenic mice treated with harmine (Tg &#x02013; Harmine, <xref ref-type="fig" rid="pone-0007540-g006">Fig. 6A</xref>), which shows that treatment with harmine prevents the increase of SAHH activity in Tg 189N3 mice. Moreover, even if harmine treatment has no effect on NQO1 in non transgenic mice (Tg &#x02013; Harmine, <xref ref-type="fig" rid="pone-0007540-g006">Fig. 6B</xref>), treatment with harmine in Tg 189N3 mice (Tg 189N3 Harmine, <xref ref-type="fig" rid="pone-0007540-g006">Fig. 6B</xref>) reduced NQO1 activity compared to non treated Tg 189N3 mice (Tg 189N3 Vehicle, <xref ref-type="fig" rid="pone-0007540-g006">Fig. 6B</xref>).</p><fig id="pone-0007540-g006" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0007540.g006</object-id><label>Figure 6</label><caption><title>Effects of harmine on hepatic SAHH and NQO1 activities, and on plasma Hcy levels in Tg 189N3 mice.</title><p>Hepatic SAHH (A) and NQO1 (B) activities are presented as percent of untreated (Vehicle) non-transgenic (Tg &#x02013;) mice activities. (C) Plasma Hcy level. Data correspond to means &#x000b1; SEM and the statistical analysis was done with one-way ANOVA followed by Student's unpaired <italic>t</italic>-test. n&#x0200a;&#x0003d;&#x0200a;number of mice.</p></caption><graphic xlink:href="pone.0007540.g006"/></fig><p>To confirm the implication of Dyrk1a on Hcy level, we also assayed plasma Hcy levels in harmine-treated non-transgenic and Tg 189N3 mice. There was a trend towards a 1.4 fold increase of plasma Hcy concentration in harmine treated Tg 189N3 (Tg 189N3 Harmine, <xref ref-type="fig" rid="pone-0007540-g006">Fig. 6C</xref>) compared to non-treated Tg 189N3 mice (Tg 189N3 Vehicle, <xref ref-type="fig" rid="pone-0007540-g006">Fig. 6C</xref>) although this was not statistically significant.</p></sec><sec id="s2f"><title>SAHH and NQO1 activities were increased in lymphoblastoid cell lines</title><p>In order to determine whether the activities observed in mice does apply to humans, we also analyzed the SAHH and NQO1 activity in lymphoblastoid cell lines (LCLs) from patients with DS. We first confirmed that LCLs from patients with DS (T21, <xref ref-type="table" rid="pone-0007540-t004">Table 4</xref>) overexpressed 1.5 fold DYRK1A at the mRNA and protein level compared to LCLs from control individuals (control, <xref ref-type="table" rid="pone-0007540-t004">Table 4</xref>). We not only found an increased SAHH activity but also a decreased mRNA <italic>SAHH</italic> expression in LCLs from patients with DS compared to LCLs from control individuals (<xref ref-type="table" rid="pone-0007540-t004">Table 4</xref>). Moreover, the NQO1 activity was also increased in LCLs from patients with DS, concomitant with an increased mRNA expression (<xref ref-type="table" rid="pone-0007540-t004">Table 4</xref>).</p><table-wrap id="pone-0007540-t004" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0007540.t004</object-id><label>Table 4</label><caption><title>Relative expression of DYRK1A, SAHH and NQO1 and SAHH and NQO1 activities obtained from lymphoblastoid cell lines.</title></caption><alternatives><graphic id="pone-0007540-t004-4" xlink:href="pone.0007540.t004"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Genotype</td><td align="left" rowspan="1" colspan="1">DYRK1A mRNA expression (&#x00025; of control)</td><td align="left" rowspan="1" colspan="1">DYRK1A protein expression (&#x00025; of control)</td><td align="left" rowspan="1" colspan="1">SAHH mRNA expression (&#x00025; of control)</td><td align="left" rowspan="1" colspan="1">SAHH activity (&#x00025; of control)</td><td align="left" rowspan="1" colspan="1">NQO1 mRNA expression (&#x00025; of control)</td><td align="left" rowspan="1" colspan="1">NQO1 activity (&#x00025; of control)</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">control</td><td align="left" rowspan="1" colspan="1">100&#x000b1;9.3 (n&#x0200a;&#x0003d;&#x0200a;12)</td><td align="left" rowspan="1" colspan="1">100&#x000b1;9.6 (n&#x0200a;&#x0003d;&#x0200a;16)</td><td align="left" rowspan="1" colspan="1">100&#x000b1;19.3 (n&#x0200a;&#x0003d;&#x0200a;12)</td><td align="left" rowspan="1" colspan="1">100&#x000b1;8.7 (n&#x0200a;&#x0003d;&#x0200a;10)</td><td align="left" rowspan="1" colspan="1">99.9&#x000b1;11 (n&#x0200a;&#x0003d;&#x0200a;11)</td><td align="left" rowspan="1" colspan="1">100&#x000b1;16 (n&#x0200a;&#x0003d;&#x0200a;6)</td></tr><tr><td align="left" rowspan="1" colspan="1">T21</td><td align="left" rowspan="1" colspan="1">150.8&#x000b1;10.3<bold><sup>&#x02020;</sup></bold> (n&#x0200a;&#x0003d;&#x0200a;12)</td><td align="left" rowspan="1" colspan="1">154.3&#x000b1;15.6<bold><sup>&#x02020;</sup></bold> (n&#x0200a;&#x0003d;&#x0200a;16)</td><td align="left" rowspan="1" colspan="1">53.8&#x000b1;6.5&#x0002a; (n&#x0200a;&#x0003d;&#x0200a;12)</td><td align="left" rowspan="1" colspan="1">135.5&#x000b1;12.8&#x0002a; (n&#x0200a;&#x0003d;&#x0200a;12)</td><td align="left" rowspan="1" colspan="1">160.9&#x000b1;14.6<bold><sup>&#x02020;</sup></bold> (n&#x0200a;&#x0003d;&#x0200a;11)</td><td align="left" rowspan="1" colspan="1">228&#x000b1;55&#x0002a; (n&#x0200a;&#x0003d;&#x0200a;6)</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt104"><label/><p>The values of lymphoblastoid cell lines (LCLs) from patients with DS (T21) were normalized to the mean lymphoblastoid cell lines from control individuals (control). Data correspond to means &#x000b1; SEM and the statistical analysis was done by Student's unpaired <italic>t</italic>-tests. n&#x0200a;&#x0003d;&#x0200a;number of LCLs. &#x0002a; <italic>p</italic>&#x0003c;0.05; <bold><sup>&#x02020;</sup></bold><italic>p</italic>&#x0003c;0.006.</p></fn></table-wrap-foot></table-wrap></sec></sec><sec id="s3"><title>Discussion</title><p>Elevated plasma Hcy level is well recognized as an important vascular risk factor and atherosclerosis in the coronary, cerebrovascular and peripheral arterial circulation, even if the degree of hyperhomocysteinemia is moderate <xref ref-type="bibr" rid="pone.0007540-Welch1">&#x0005b;2&#x0005d;</xref>. On the contrary, adults with Down syndrome seem to be protected against atherosclerosis, despite having elevated risk factors, such as elevated total body fat, higher levels of triglycerides and C-reactive protein, and lower levels of moderate to vigorous physical activity <xref ref-type="bibr" rid="pone.0007540-Draheim2">&#x0005b;24&#x0005d;</xref>. As we found a negative correlation between plasma Hcy levels and hepatic DYRK1A expression which underlines the effect of hyperhomocysteinemia on DYRK1A expression <xref ref-type="bibr" rid="pone.0007540-Hamelet1">&#x0005b;10&#x0005d;</xref>, we decided to analyze the over-expression of DYRK1A on Hcy metabolism. Here we show that overexpression of DYRK1A diminishes the plasma Hcy level. This result was obtained with different murine models which contain the human or the murine gene, with duplications of increasing complexity and over-expression of Dyrk1a. Therefore, we see an effect of Hcy level on DYRK1A expression <xref ref-type="bibr" rid="pone.0007540-Hamelet1">&#x0005b;10&#x0005d;</xref>, but also an effect of DYRK1A expression on Hcy level, which is underlined by the correlation between plasma Hcy level and hepatic DYRK1A protein expression (10 and <xref ref-type="fig" rid="pone-0007540-g005">Figure 5</xref>).</p><p>As increased expression of DYRK1A and low plasma Hcy levels have been associated with DS <xref ref-type="bibr" rid="pone.0007540-Licastro1">&#x0005b;6&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007540-Pogribna1">&#x0005b;11&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0007540-Galletti1">&#x0005b;13&#x0005d;</xref>, we also analyzed the contribution of DYRK1A on Hcy levels in a mouse trisomic complex, the Ts65Dn mice. We found an increased expression of DYRK1A in liver and a decreased level of plasma Hcy level in Ts65Dn. <italic>DYRK1A</italic> and <italic>CBS</italic> are two genes located on chromosome 21. Our results show that over-expression of DYRK1A has no effect on CBS activity, which is in agreement with the hepatic SAM levels (an allosteric activator of CBS). It has been demonstrated that DS children have increased cystathionine level relative to normal children, consistent with over-expression of the CBS gene present on human chromosome 21 and mouse chromosome 17 <xref ref-type="bibr" rid="pone.0007540-Pogribna1">&#x0005b;11&#x0005d;</xref>. On the one hand, the over-expression of CBS in DS is the predominant mechanism to explain the decrased plasma Hcy level in DS patients <xref ref-type="bibr" rid="pone.0007540-Pogribna1">&#x0005b;11&#x0005d;</xref>. On the other hand, the DYRK1A over-expression likely plays a role on decreased plasma Hcy level in DS patients however, to a lesser extent.</p><p>We showed that over-expression of DYRK1A increases the SAHH activity not only in mice, but also in LCLs obtained from DS patients. Moreover, treatment with harmine, the most potent and specific inhibitor of Dyrk1a <xref ref-type="bibr" rid="pone.0007540-Bain1">&#x0005b;22&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007540-Kuhn1">&#x0005b;23&#x0005d;</xref>, demonstrates that the increased SAHH activity depends on Dyrk1A kinase activity. We also established a correlation between plasma Hcy level, hepatic DYRK1A protein expression and hepatic SAHH activity. However, the increased hepatic SAHH activity was not associated with statistical difference in hepatic SAH levels. A previous study showed a lower concentration of plasma Hcy and SAH levels in DS children than in plasma of control subjects <xref ref-type="bibr" rid="pone.0007540-Pogribna1">&#x0005b;11&#x0005d;</xref>. Galletti et al. also demonstrated that the intracellular concentration of SAH is significantly reduced in DS erythrocytes, paralleling the low plasma Hcy levels, and the intracellular SAM concentration is the same as in the control cells <xref ref-type="bibr" rid="pone.0007540-Galletti1">&#x0005b;13&#x0005d;</xref>. Therefore the diminution of SAH levels could be due to other genes located on chromosome 21. We found a decreased hepatic SAM levels, associated with a decrease of the SAM/SAH ratio in Ts65Dn, which suggests an altered SAM-dependent methylation, but not in Tg 152F7 and Tg 189N3 mice. Interestingly, Ts65Dn mice also contain three copies of DNMTa1 gene, which encodes for a DNA methyltransferase. The over-expression of this DNA methyltransferase could decrease SAM level and the SAM/SAH ratio in liver of Ts65Dn mice, which could influence the methylation index and then the gene expression.</p><p>SAHH cleaves SAH to adenosine and Hcy, but this reaction is easily reversible by the same enzyme <xref ref-type="bibr" rid="pone.0007540-Kloor1">&#x0005b;25&#x0005d;</xref>. Although the equilibrium dynamics of the SAHH reaction strongly favor SAH formation, under physiological conditions, the rapid metabolism of SAHH end products Hcy (via transsulfuration and remethylation pathways) and adenosine (via the adenosine deaminase or adenosine kinase) drive the SAHH reaction in the hydrolysis direction. The activation of the SAHH activity in the reverse direction would be expected to promote the diminution of Hcy. The finding that DYRK1A over-expression activated SAHH activity is novel and is also consistent with no limitation of the remethylation pathway. We found an increased expression of the three enzymes implicated in the remethylation pathway in liver of Tg189N3 mice. However, the SAHH expression was decreased not only in liver of Tg 189N3 and Ts65Dn mice, but also in LCLs from DS patients. Because SAHH transcripts were decreased, the finding of increased SAHH activity must represent a post-transcriptional modification of the enzyme. The activation of SAHH activity can be due to a direct or an indirect mechanism. We found an increased activity of NQO1 not only in liver of Tg 152F7, Tg 189N3 and Ts65Dn mice, but also in LCLs obtained from DS patients. Moreover, treatment with harmine demonstrates that the increased NQO1 activity depends on Dyrk1A kinase activity. The increased activity of NQO1 is followed by an increase of a by-product of the enzyme reaction, NAD&#x0002b;, which is a cofactor of SAHH <xref ref-type="bibr" rid="pone.0007540-Hershfield1">&#x0005b;21&#x0005d;</xref>. NQO1 is an inducible enzyme, and its overexpression protects cells against cell death <xref ref-type="bibr" rid="pone.0007540-Han1">&#x0005b;26&#x0005d;</xref>. The cell's major strategy of coping with oxidative stress is to increase the anti-oxidative potential by upregulating defense enzymes through activation of the nuclear factor-E2-related factor-2 (Nrf2). Nrf2 can activate many phase II detoxifying and antioxidant genes including NQO1 <xref ref-type="bibr" rid="pone.0007540-Aleksunes1">&#x0005b;27&#x0005d;</xref>. Nrf2 dissociates from the cytoskeletal binding protein KEAP1 and translocates to the nucleus in response to oxidative stress. It has been demonstrated that the PI3K/Akt pathways facilitate the release of NRF2 from KEAP1 and its subsequent translocation, and regulate ROS-dependent Nrf2 activation <xref ref-type="bibr" rid="pone.0007540-Joung1">&#x0005b;28&#x0005d;</xref>. Previous results have shown that phosphorylation of protein kinase Akt was increased in Ts65Dn mice, and we found an increased hepatic NQO1 activity in these mice <xref ref-type="bibr" rid="pone.0007540-Siarey1">&#x0005b;29&#x0005d;</xref>. Then over-expression of DYRK1A could modulate the hepatic SAHH activity through an indirect mechanism initiated by its serine/threonine kinase activity.</p><p>In conclusion, our results might give clues to understand the protective effect of DS against vascular defect through a decrease of Hcy level, and a link between metabolomics and signalling pathways.</p></sec><sec sec-type="methods" id="s4"><title>Methods</title><sec id="s4a"><title>Mice and genotyping</title><p>Mice were maintained in a controlled environment with unlimited access to food and water on 12 h light/dark cycle. All procedures were carried out in accordance with internal guidelines of the French Agriculture Ministry for animal handing. Number of mice and suffering were minimized as possible. Mice heterozygous for targeted disruption of the <italic>Cbs</italic> gene (<italic>Cbs</italic><sup>&#x0002b;/&#x02212;</sup>) were generously donated by Dr. N. Maeda (Department of Pathology, University of North Carolina, Chaped Hill, NC, USA) <xref ref-type="bibr" rid="pone.0007540-Watanabe1">&#x0005b;14&#x0005d;</xref>. <italic>Cbs</italic><sup>&#x0002b;/&#x02212;</sup> mice, on a C57BL/6 background were obtained by mating male <italic>Cbs</italic><sup>&#x0002b;/&#x02212;</sup> mice with female wild-type C57BL/6 (<italic>Cbs</italic><sup>&#x0002b;/&#x0002b;</sup>) mice. DNA isolated from 4 week-aged mice tail biopsies was subjected to genotyping of the targeted CBS allele using a polymerase chain reaction (PCR) assay <xref ref-type="bibr" rid="pone.0007540-Watanabe1">&#x0005b;14&#x0005d;</xref>. The human yeast artificial chromosome 152 F7 (YAC-152F7) strain has been previously described <xref ref-type="bibr" rid="pone.0007540-Smith2">&#x0005b;30&#x0005d;</xref>. This transgenic line (Tg 152F7) contains the genes PIGP, TTC3, DSCR9, DSCR3 and DYRK1A. The YAC-152F7 line, which was constructed in an FVB/N background, was backcrossed on a C57BL/6 background. Genotyping was performed by PCR using specific human primers <xref ref-type="bibr" rid="pone.0007540-Smith2">&#x0005b;30&#x0005d;</xref>. <italic>Cbs</italic><sup>&#x0002b;/&#x02212;</sup> and Tg 152F7 mice, on the same background, were crossbred. Male from each genotype from the same litter, two months of age, were used. The murine bacterial artificial chromosome 189 N3 (BAC-189N3) strain has been constructed by electroporating HM-1 embryonic stem (ES) cells with the retrofitted BAC-189N3. ES clone was selected for overexpression of Dyrk1a, and injected into blastocysts (J Delabar, personal communication). Female Tg 189N3 mice and control from the same litter, two months of age, were used. Ts65Dn mice possess a third copy of a region of mouse chromosome 16 from <italic>App</italic> to <italic>Mx1</italic>, orthologous to the DS critical region of HSA 21 <xref ref-type="bibr" rid="pone.0007540-Reeves1">&#x0005b;31&#x0005d;</xref>. Male Ts65Dn mice and control, from the same litter, six months of age, were used.</p></sec><sec id="s4b"><title>Harmine treatment</title><p>Mice were injected intraperitoneally overnight, with 10 mg/kg of harmine hydrochloride hydrate (Fisher Scientific, Illkirch, France) dissolved in 0.9&#x00025; NaCl. The next morning, mice were injected once more for 1 hour. Control mice were injected with 0.9&#x00025; NaCl.</p></sec><sec id="s4c"><title>Preparation of serum samples, tissue collection, and plasma total Hcy assay</title><p>At the time of sacrifice, blood samples were collected into tubes containing a 1/10 volume of 3.8&#x00025; sodium citrate, placed on ice immediately. Plasma was isolated by centrifugation at 2500 <italic>g</italic> for 15 min at 4&#x000b0;C. Liver was harvested, snap-frozen and stored at &#x02212;80&#x000b0;C until use. Plasma total Hcy was assayed by using the fluorimetric high-performance liquid chromatography method described by Fortin and Genest <xref ref-type="bibr" rid="pone.0007540-Fortin1">&#x0005b;32&#x0005d;</xref>. The inter- and intra-assay coefficients of variation for mean tHcy level were 4.2&#x00025; and 6.3&#x00025; respectively and the linearity was from 1 to 100 &#x000b5;M <xref ref-type="bibr" rid="pone.0007540-Ducros1">&#x0005b;33&#x0005d;</xref>.</p></sec><sec id="s4d"><title>Cell Lines and Culture Conditions</title><p>Epstein&#x02013;Barr virus-transformed lymphoblastoid cell lines (LCLs) are derived from healthy individuals and unrelated DS patients, recruited from the Institut J&#x000e9;r&#x000f4;me Lejeune (Paris, France) and the CHU Saint-Etienne (France). Written informed consent was obtained from the participants or from their families, and the French biomedical ethics committee gave its approval for this study (Comit&#x000e9; de Protection des Personnes dans la Recherche Biom&#x000e9;dicale number 2003&#x02013;036 and 2005&#x02013;06). DS was confirmed by karyotyping before and after Epstein&#x02013;Barr virus transformation. Culture media consisted of Opti-MEM with GlutaMax (Invitrogen, Cergy, France) supplemented with 5&#x00025; fetal bovine serum from a unique batch and 1&#x00025; penicillin and streptomycin mix (10,000 U/mL). Cell lines were grown at 37&#x000b0;C in humidified incubators, in an atmosphere of 5&#x00025; CO<sub>2</sub>. Cells were harvested by centrifugation, washed in 5 mL PBS, followed by another centrifugation, and stored at &#x02212;80&#x000b0;C.</p></sec><sec id="s4e"><title>Determination of hepatic SAM and SAH concentrations</title><p>Levels of SAM and SAH in liver tissues were determined by stable isotope dilution liquid chromatography tandem mass spectrometry in an adapted method from Gellekink et al. <xref ref-type="bibr" rid="pone.0007540-Gellekink1">&#x0005b;34&#x0005d;</xref>. In brief, frozen tissues were homogenized with ice-cold perchloric acid then centrifugated. Supernatant cleanup was performed with solid phase extraction (SPE) columns after neutralization of the acidified samples. The type of SPE cartridges used is phenyl boronic acid (SPE Bond Elut &#x02013; PBA, 100 mg) from Varian (Courtaboeuf, les Ulis, France). Two isotopically labeled internal standards were used : <sup>13</sup>C<sub>5</sub>-SAH and D<sub>3</sub>-SAM. Analytes were detected using the transitions m/z 399&#x02013;250 (SAM), 402&#x02013;250 (D<sub>3</sub>-SAM), 385&#x02013;136 (SAH), 390&#x02013;136 (<sup>13</sup>C<sub>5</sub>-SAH) for quantification and the transitions m/z 399&#x02013;136 (SAM), 402&#x02013;136 (D<sub>3</sub>-SAM), 385&#x02013;134 (SAH), 390&#x02013;134 (<sup>13</sup>C<sub>5</sub>-SAH) for qualification. The detection limits (signal-to-noise ratio&#x0200a;&#x0003d;&#x0200a;3), estimated from the lower calibration point, were 0.4 nmol/L for SAM and 0.6 nmol/L for SAH. The variability of the assay expressed as CVs (n&#x0200a;&#x0003d;&#x0200a;4) were 13.3&#x00025; for SAM and 9.6&#x00025; for SAH with a plasma pool containing 130 nmol/L of SAM and 11 nmol/L of SAH.</p></sec><sec id="s4f"><title>Western blot analysis</title><p>Proteins preparations were subjected to SDS electrophoresis on 7.5&#x00025; acrylamide gels under reducing conditions and transferred to Hybond-C Extra membrane (GE Healthcare Europe GmbH, Saclay, France). After transfer, membranes were blocked in 10&#x00025; nonfat dry milk in Tris-saline buffer (1.5 mM Tris, 5 mM NaCl, 0.1&#x00025; Tween 20) and probed overnight at 4&#x000b0;C with DYRK1A antibody (1/500) (Abnova corporation, Tebu, France). Horseradish peroxidase-conjugated secondary antibody and Western Blotting Luminol Reagent (Santa Cruz Biotechnology, Tebu, France) were used to detect specific proteins. &#x003b2;-actin (1/4000) (Sigma-Aldrich, France) was used as an internal control. Digitized images of the immunoblots obtained using a LAS-3000 imaging system (Fuji Photo Film Co., Ltd.) were used for densitometric measurements with an image analyzer (UnScan It software, Silk Scientific Inc.).</p></sec><sec id="s4g"><title>Enzyme Activity assays</title><p>Determination of CBS activity was assayed on 400 &#x000b5;g of total proteins obtained from liver samples, determined by Bradford method, as described <xref ref-type="bibr" rid="pone.0007540-Miller1">&#x0005b;35&#x0005d;</xref>. Proteins were incubated for 1h at 37&#x000b0;C with 1 mM of propargylglycine, 0.2 mM of pyridoxal phosphate, 10 mM of L-serine, 10 mM of DL-Hcy, 0.4 mM of SAM, using DTNB (5,5&#x02032;-dithiobis-(2-nitrobenzoic acid)) based-assay. All the chemical products were obtained from Sigma (Sigma-Aldrich, France). Determination of SAH hydrolase activity was assayed on 300 &#x000b5;g of total proteins obtained from liver samples or lymphoblastoid cell lines following the protocol described by Villanueva and Halsted <xref ref-type="bibr" rid="pone.0007540-Villanueva1">&#x0005b;36&#x0005d;</xref>. Determination of NQO1 activity was assayed on 150 &#x000b5;g of total proteins obtained from liver samples or lymphoblastoid cell lines following the protocol described by Ernster <xref ref-type="bibr" rid="pone.0007540-Ernster1">&#x0005b;37&#x0005d;</xref>, modified by Benson et al. <xref ref-type="bibr" rid="pone.0007540-Benson1">&#x0005b;38&#x0005d;</xref>.</p></sec><sec id="s4h"><title>RNA extraction and determination of mRNA levels</title><p>Total RNA was prepared from mice liver with the Nucleospin&#x000ae; RNA II kit (Macherey-Nagel, Hoerdt). The quantity and purity of the RNA was assessed by measuring absorbance at 260 and 280 nm. Reverse transcription was carried out on 2 &#x000b5;g total RNA as described by the manufacturer (Ambion, UK). The mRNA levels were assessed by quantitative RT-PCR (Q-PCR). cDNA (0.4 &#x000b5;L) was diluted with PCR mix (Light Cycler FastStart DNA Master SYBR Green I Kit, Roche Diagnostics) containing a final concentration of 3 mM MgCl<sub>2</sub> and 0.5 &#x000b5;M of primers in a final volume of 10 &#x000b5;L. The primers were designed by Primer 3 software. The primers pairs were selected to yield a single amplicon based on dissociation curves. The peptidylprolyl isomerase B (PPIB) mRNA, the hypoxanthine phosphoribosyltransferase (HPRT) mRNA, the fasciculation and elongation zeta protein 1 (fez), and the Zinc finger protein (AB000468) mRNA were used as an endogenous control. Primer sequences were given in the <xref ref-type="table" rid="pone-0007540-t005">table 5</xref>. Q-PCR was performed on total RNA isolated from liver of individual mice or from individual LCLs in a Lightcycler system (Roche Diagnostics). The thermal cycler parameters were as follows : hold for 8 min at 95&#x000b0;C for one cycle followed by amplification of cDNA for 40 cycles with melting for 5 s at 95&#x000b0;C, annealing for 5 s at 65&#x000b0;C and extension for 10 s at 72&#x000b0;C. Each reaction was performed in triplicate. Subsequent assay efficiency calculations were carried out in Light Cycler Relative Quantification Software (Roche Diagnostics). As the efficiency of the target gene and the control genes were comparable, &#x00394;Cp analysis of the results allows to assess the ratio of the target mRNA versus control mRNA <xref ref-type="bibr" rid="pone.0007540-Tichopad1">&#x0005b;39&#x0005d;</xref>.</p><table-wrap id="pone-0007540-t005" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0007540.t005</object-id><label>Table 5</label><caption><title>Primer sequences for real-time quantitative reverse transcription-polymerase chain reaction (Q-PCR) (all primers are listed 5&#x02032; to 3&#x02032;).</title></caption><alternatives><graphic id="pone-0007540-t005-5" xlink:href="pone.0007540.t005"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">mRNA</td><td align="left" rowspan="1" colspan="1">Forward</td><td align="left" rowspan="1" colspan="1">Reverse</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">hDYRK1A</td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">TTGAAACGCCACTTTATGTTTCG</named-content></td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">CCCAGTAGCACCTCTGGAGACC</named-content></td></tr><tr><td align="left" rowspan="1" colspan="1">hHPRT</td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">GCTGTGGATGCTGTGAAGAA</named-content></td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">GCCTCTTCAAGCCAGTAACG</named-content></td></tr><tr><td align="left" rowspan="1" colspan="1">hAB000468</td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">CAAGAAAGCGTCGTGGTGGA</named-content></td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">ATCGTCACTGCTCACCACAC</named-content></td></tr><tr><td align="left" rowspan="1" colspan="1">hNQO1</td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">GCCGCAGACCTTGTGATATTCC</named-content></td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">GCCACTCTGAATTGGCCAGAGA</named-content></td></tr><tr><td align="left" rowspan="1" colspan="1">hSAHH</td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">TCCGAGGCATCTCTGAGGAGAC</named-content></td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">AGCCTGCTACCACCGCTACCTT</named-content></td></tr><tr><td align="left" rowspan="1" colspan="1">mBHMT</td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">GCGTGAGCCAGACGCCTTCATACCTTAG</named-content></td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">CCTTTCTGGGGCCAACTCCTCTGCAATC</named-content></td></tr><tr><td align="left" rowspan="1" colspan="1">mDYRK1A</td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">ATCCGACGCACCAGCATC</named-content></td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">AATTGTAGACCCTTGGCCTGGT</named-content></td></tr><tr><td align="left" rowspan="1" colspan="1">mfez</td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">TCACGGAGCCAGCATGAATCAG</named-content></td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">GGGGAAAAGTCTTGCCGTTCCA</named-content></td></tr><tr><td align="left" rowspan="1" colspan="1">mHPRT</td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">CTCATGGACTGATTATGGACAGGAC</named-content></td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">GCAGGTCAGCAAAGAACTTATAGCC</named-content></td></tr><tr><td align="left" rowspan="1" colspan="1">mMAT1a</td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">CAGGTGTCCTATGCCATTGGT</named-content></td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">GTAGCACGCAGTCTTCTGGTAGAT</named-content></td></tr><tr><td align="left" rowspan="1" colspan="1">mMS</td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">CCGAGGGATGGAAGCCATTCGAGAAGCA</named-content></td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">GTGGCCAACAGCCTTCTTCATGACACGG</named-content></td></tr><tr><td align="left" rowspan="1" colspan="1">mMTHFR</td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">ATGGACTCTGGTGACAAGTGG</named-content></td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">AGTGGTCACCTACAGGGTCTCC</named-content></td></tr><tr><td align="left" rowspan="1" colspan="1">mNQO1</td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">GCCATGAAGGAGGCTGCTGT</named-content></td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">ATCTGGGCTCAGGCGTCCTT</named-content></td></tr><tr><td align="left" rowspan="1" colspan="1">mPPIB</td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">GGATTTGGCTACAAAAACAGCAA</named-content></td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">AGCCAGGCCCGTAGTGCTTC</named-content></td></tr><tr><td align="left" rowspan="1" colspan="1">mSAHH</td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">ACCCTGTTGGGGTTCACTTCCT</named-content></td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">TGACATTTGCTCTTGGGAACGA</named-content></td></tr></tbody></table></alternatives></table-wrap></sec><sec id="s4i"><title>Data analysis</title><p>Statistical analysis was done with one-way ANOVA followed by Student's unpaired <italic>t</italic>-test using Statview software. In both cases, Student-Newman-Keuls tests were used for multiple pairwise comparaisons. The results are expressed as mean &#x000b1; SEM. Correlations between Hcy level, DYRK1A protein expression and SAHH activity were determined by using Spearman's rank correlation as data were not normally distributed according to Shapiro &#x02013; Wilk test. The multivariate analysis was performed according to the principal component analysis (PCA). Data were analyzed using R software (<ext-link ext-link-type="uri" xlink:href="http://www.R-project.org">http://www.R-project.org</ext-link>) and considered significant when <italic>p</italic>&#x0003c;0.05. A <italic>p</italic> value of 0.06&#x02013;0.10 was considered to indicate a strong statistical tendency due to the small sample size.</p></sec></sec><sec id="s5"><title/></sec></body><back><ack><p>We thank Dr N. Maeda (Department of Pathology, University of North Carolina, Chapel Hill, NC) for providing heterozygous <italic>Cbs</italic> mice. We thank C. Imbert, F. Lequellec, A. Ledru and A. Djemat for technical assistance.</p></ack><ref-list><title>References</title><ref id="pone.0007540-Selhub1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Selhub</surname><given-names>J</given-names></name></person-group><year>1999</year><article-title>Homocysteine metabolism.</article-title><source>Annu Rev Nutr</source><volume>19</volume><fpage>217</fpage><lpage>246</lpage><pub-id pub-id-type="pmid">10448523</pub-id></mixed-citation></ref><ref id="pone.0007540-Welch1"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Welch</surname><given-names>GN</given-names></name><name><surname>Loscalzo</surname><given-names>J</given-names></name></person-group><year>1998</year><article-title>Homocysteine and atherothrombosis.</article-title><source>N Engl J Med</source><volume>338</volume><fpage>1042</fpage><lpage>1050</lpage><pub-id pub-id-type="pmid">9535670</pub-id></mixed-citation></ref><ref id="pone.0007540-Murdoch1"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murdoch</surname><given-names>JC</given-names></name><name><surname>Rodger</surname><given-names>JC</given-names></name><name><surname>Rao</surname><given-names>SS</given-names></name><name><surname>Fletcher</surname><given-names>CD</given-names></name><name><surname>Dunnigan</surname><given-names>MG</given-names></name></person-group><year>1977</year><article-title>Down's syndrome: an atheroma-free model?</article-title><source>Br Med J</source><volume>2</volume><fpage>226</fpage><lpage>228</lpage><pub-id pub-id-type="pmid">141966</pub-id></mixed-citation></ref><ref id="pone.0007540-Draheim1"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Draheim</surname><given-names>CC</given-names></name></person-group><year>2006</year><article-title>Cardiovascular disease prevalence and risk factors of persons with mental retardation.</article-title><source>Ment Retard Dev Disabil Res Rev</source><volume>12</volume><fpage>3</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">16435328</pub-id></mixed-citation></ref><ref id="pone.0007540-YlaHerttuala1"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yla-Herttuala</surname><given-names>S</given-names></name><name><surname>Luoma</surname><given-names>J</given-names></name><name><surname>Nikkari</surname><given-names>T</given-names></name><name><surname>Kivimaki</surname><given-names>T</given-names></name></person-group><year>1989</year><article-title>Down's syndrome and atherosclerosis.</article-title><source>Atherosclerosis</source><volume>76</volume><fpage>269</fpage><lpage>272</lpage><pub-id pub-id-type="pmid">2525042</pub-id></mixed-citation></ref><ref id="pone.0007540-Licastro1"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Licastro</surname><given-names>F</given-names></name><name><surname>Marocchi</surname><given-names>A</given-names></name><name><surname>Penco</surname><given-names>S</given-names></name><name><surname>Porcellini</surname><given-names>E</given-names></name><name><surname>Lio</surname><given-names>D</given-names></name><etal/></person-group><year>2006</year><article-title>Does Down's syndrome support the Homocysteine theory of atherogenesis? Experience in elderly subjects with trisomy 21.</article-title><source>Arch Gerontol Geriatr</source><volume>43</volume><fpage>381</fpage><lpage>387</lpage><pub-id pub-id-type="pmid">16533539</pub-id></mixed-citation></ref><ref id="pone.0007540-Becker1"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Becker</surname><given-names>W</given-names></name><name><surname>Joost</surname><given-names>HG</given-names></name></person-group><year>1999</year><article-title>Structural and functional characteristics of Dyrk, a novel subfamily of protein kinases with dual specificity.</article-title><source>Prog Nucleic Acid Res Mol Biol</source><volume>62</volume><fpage>1</fpage><lpage>17</lpage><pub-id pub-id-type="pmid">9932450</pub-id></mixed-citation></ref><ref id="pone.0007540-Seifert1"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seifert</surname><given-names>A</given-names></name><name><surname>Allan</surname><given-names>LA</given-names></name><name><surname>Clarke</surname><given-names>PR</given-names></name></person-group><year>2008</year><article-title>DYRK1A phosphorylates caspase 9 at an inhibitory site and is potently inhibited in human cells by harmine.</article-title><source>FEBS J</source><volume>275</volume><fpage>6268</fpage><lpage>6280</lpage><pub-id pub-id-type="pmid">19016842</pub-id></mixed-citation></ref><ref id="pone.0007540-Laguna1"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laguna</surname><given-names>A</given-names></name><name><surname>Aranda</surname><given-names>S</given-names></name><name><surname>Barallobre</surname><given-names>MJ</given-names></name><name><surname>Barhoum</surname><given-names>R</given-names></name><name><surname>Fern&#x000e1;ndez</surname><given-names>E</given-names></name><etal/></person-group><year>2008</year><article-title>The protein kinase DYRK1A regulates caspase-9-mediated apotposis during retina development.</article-title><source>Dev Cell</source><volume>15</volume><fpage>841</fpage><lpage>853</lpage><pub-id pub-id-type="pmid">19081073</pub-id></mixed-citation></ref><ref id="pone.0007540-Hamelet1"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamelet</surname><given-names>J</given-names></name><name><surname>Noll</surname><given-names>C</given-names></name><name><surname>Ripoll</surname><given-names>C</given-names></name><name><surname>Paul</surname><given-names>JL</given-names></name><name><surname>Janel</surname><given-names>N</given-names></name><etal/></person-group><year>2009</year><article-title>Effect of hyperhomocysteinemia on the protein DYRK1A in liver of mice.</article-title><source>Biochem Biophys Res Commun</source><volume>378</volume><fpage>673</fpage><lpage>677</lpage><pub-id pub-id-type="pmid">19059382</pub-id></mixed-citation></ref><ref id="pone.0007540-Pogribna1"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pogribna</surname><given-names>M</given-names></name><name><surname>Melnyk</surname><given-names>S</given-names></name><name><surname>Pogribny</surname><given-names>I</given-names></name><name><surname>Chango</surname><given-names>A</given-names></name><name><surname>Yi</surname><given-names>P</given-names></name><etal/></person-group><year>2001</year><article-title>Homocysteine metabolism in children with Down syndrome: in vitro modulation.</article-title><source>Am J Hum Genet</source><volume>69</volume><fpage>88</fpage><lpage>95</lpage><pub-id pub-id-type="pmid">11391481</pub-id></mixed-citation></ref><ref id="pone.0007540-Dowjat1"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dowjat</surname><given-names>WK</given-names></name><name><surname>Adayev</surname><given-names>T</given-names></name><name><surname>Kuchna</surname><given-names>I</given-names></name><name><surname>Nowicki</surname><given-names>K</given-names></name><name><surname>Palminiello</surname><given-names>S</given-names></name><etal/></person-group><year>2007</year><article-title>Trisomy-driven overexpression of DYRK1A kinase in the brain of subjects with Down syndrome.</article-title><source>Neurosci Lett</source><volume>413</volume><fpage>77</fpage><lpage>81</lpage><pub-id pub-id-type="pmid">17145134</pub-id></mixed-citation></ref><ref id="pone.0007540-Galletti1"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Galletti</surname><given-names>P</given-names></name><name><surname>De Bonis</surname><given-names>ML</given-names></name><name><surname>Sorrentino</surname><given-names>A</given-names></name><name><surname>Raimo</surname><given-names>M</given-names></name><name><surname>D'Angelo</surname><given-names>S</given-names></name><etal/></person-group><year>2007</year><article-title>Accumulation of altered aspartyl residues in erythrocyte proteins from patients with Down's syndrome.</article-title><source>FEBS J</source><volume>274</volume><fpage>5263</fpage><lpage>5277</lpage><pub-id pub-id-type="pmid">17892495</pub-id></mixed-citation></ref><ref id="pone.0007540-Watanabe1"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watanabe</surname><given-names>M</given-names></name><name><surname>Osada</surname><given-names>J</given-names></name><name><surname>Aratani</surname><given-names>Y</given-names></name><name><surname>Kluckman</surname><given-names>K</given-names></name><name><surname>Reddick</surname><given-names>R</given-names></name><etal/></person-group><year>1995</year><article-title>Mice deficient in cystathionine beta-synthase: animal models for mild and severe homocyst(e)inemia.</article-title><source>Proc Natl Acad Sci U S A</source><volume>92</volume><fpage>1585</fpage><lpage>1589</lpage><pub-id pub-id-type="pmid">7878023</pub-id></mixed-citation></ref><ref id="pone.0007540-Smith1"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>DJ</given-names></name><name><surname>Stevens</surname><given-names>ME</given-names></name><name><surname>Sudanagunta</surname><given-names>SP</given-names></name><name><surname>Bronson</surname><given-names>RT</given-names></name><name><surname>Makhinson</surname><given-names>M</given-names></name><etal/></person-group><year>1997</year><article-title>Functional screening of 2 Mb of human chromosome 21q22.2 in transgenic mice implicates minibrain in learning defects associated with Down syndrome.</article-title><source>Nat Genet</source><volume>16</volume><fpage>28</fpage><lpage>36</lpage><pub-id pub-id-type="pmid">9140392</pub-id></mixed-citation></ref><ref id="pone.0007540-Davisson1"><label>16</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Davisson</surname><given-names>MT</given-names></name><name><surname>Schmidt</surname><given-names>C</given-names></name><name><surname>Reeves</surname><given-names>RH</given-names></name><name><surname>Irving</surname><given-names>NG</given-names></name><name><surname>Akeson</surname><given-names>EC</given-names></name><etal/></person-group><year>1993</year><article-title>Segmental trisomy as a mouse model for Down syndrome.</article-title><person-group person-group-type="editor"><name><surname>Epstein</surname><given-names>CJ</given-names></name></person-group><source>The phenotypic mapping of Down syndrome and other aneuploid conditions: progress in clinical and biological research</source><publisher-loc>New York</publisher-loc><publisher-name>Wiley-Liss</publisher-name><fpage>117</fpage><lpage>33</lpage></mixed-citation></ref><ref id="pone.0007540-Davisson2"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davisson</surname><given-names>MT</given-names></name><name><surname>Schmidt</surname><given-names>C</given-names></name><name><surname>Reeves</surname><given-names>RH</given-names></name><name><surname>Irving</surname><given-names>NG</given-names></name><name><surname>Akeson</surname><given-names>EC</given-names></name><etal/></person-group><year>1993</year><article-title>Segmental trisomy as a mouse model for Down syndrome.</article-title><source>Prog Clin Biol Res</source><volume>384</volume><fpage>117</fpage><lpage>133</lpage><pub-id pub-id-type="pmid">8115398</pub-id></mixed-citation></ref><ref id="pone.0007540-Holtzman1"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holtzman</surname><given-names>DM</given-names></name><name><surname>Santucci</surname><given-names>D</given-names></name><name><surname>Kilbridge</surname><given-names>J</given-names></name><name><surname>Chua-Couzens</surname><given-names>J</given-names></name><name><surname>Fontana</surname><given-names>DJ</given-names></name><etal/></person-group><year>1996</year><article-title>Developmental abnormalities and age-related neurodegeneration in a mouse model of Down syndrome.</article-title><source>Proc Natl Acad Sci U S A</source><volume>93</volume><fpage>13333</fpage><lpage>13338</lpage><pub-id pub-id-type="pmid">8917591</pub-id></mixed-citation></ref><ref id="pone.0007540-Finkelstein1"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Finkelstein</surname><given-names>JD</given-names></name></person-group><year>1998</year><article-title>The metabolism of homocysteine: pathways and regulation.</article-title><source>Eur J Pediatr</source><volume>157</volume><fpage>S40</fpage><lpage>44</lpage><pub-id pub-id-type="pmid">9587024</pub-id></mixed-citation></ref><ref id="pone.0007540-Stead1"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stead</surname><given-names>LM</given-names></name><name><surname>Brosnan</surname><given-names>ME</given-names></name><name><surname>Brosnan</surname><given-names>JT</given-names></name></person-group><year>2000</year><article-title>Characterization of homocysteine metabolism in the rat liver.</article-title><source>Biochem J</source><volume>350</volume><fpage>685</fpage><lpage>692</lpage><pub-id pub-id-type="pmid">10970780</pub-id></mixed-citation></ref><ref id="pone.0007540-Hershfield1"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hershfield</surname><given-names>MS</given-names></name><name><surname>Aiyar</surname><given-names>VN</given-names></name><name><surname>Premakumar</surname><given-names>R</given-names></name><name><surname>Small</surname><given-names>WC</given-names></name></person-group><year>1985</year><article-title>S-Adenosylhomocysteine hydrolase from human placenta. Affinity purification and characterization.</article-title><source>Biochem J</source><volume>230</volume><fpage>43</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">4052045</pub-id></mixed-citation></ref><ref id="pone.0007540-Bain1"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bain</surname><given-names>J</given-names></name><name><surname>Plater</surname><given-names>L</given-names></name><name><surname>Elliott</surname><given-names>M</given-names></name><name><surname>Shpiro</surname><given-names>N</given-names></name><name><surname>Hastie</surname><given-names>CJ</given-names></name><etal/></person-group><year>2007</year><article-title>The selectivity of protein kinase inhibitors: a further update.</article-title><source>Biochem J</source><volume>408</volume><fpage>297</fpage><lpage>315</lpage><pub-id pub-id-type="pmid">17850214</pub-id></mixed-citation></ref><ref id="pone.0007540-Kuhn1"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuhn</surname><given-names>C</given-names></name><name><surname>Frank</surname><given-names>D</given-names></name><name><surname>Will</surname><given-names>R</given-names></name><name><surname>Jaschinski</surname><given-names>C</given-names></name><name><surname>Frauen</surname><given-names>R</given-names></name><etal/></person-group><year>2009</year><article-title>DYRK1A Is a Novel Negative Regulator of Cardiomyocyte Hypertrophy.</article-title><source>J Biol Chem</source><volume>284</volume><fpage>17320</fpage><lpage>17327</lpage><pub-id pub-id-type="pmid">19372220</pub-id></mixed-citation></ref><ref id="pone.0007540-Draheim2"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Draheim</surname><given-names>CC</given-names></name><name><surname>Williams</surname><given-names>DP</given-names></name><name><surname>McCubbin</surname><given-names>JA</given-names></name></person-group><year>2002</year><article-title>Prevalence of physical inactivity and recommended physical activity in community-based adults with mental retardation.</article-title><source>Ment Retard</source><volume>40</volume><fpage>436</fpage><lpage>444</lpage><pub-id pub-id-type="pmid">12408746</pub-id></mixed-citation></ref><ref id="pone.0007540-Kloor1"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kloor</surname><given-names>D</given-names></name><name><surname>Fuchs</surname><given-names>S</given-names></name><name><surname>Petroktistis</surname><given-names>F</given-names></name><name><surname>Delabar</surname><given-names>U</given-names></name><name><surname>M&#x000fc;hlbauer</surname><given-names>B</given-names></name><etal/></person-group><year>1998</year><article-title>Effects of ions on adenosine binding and enzyme activity of purified S-adenosylhomocysteine hydrolase from bovine kidney.</article-title><source>Biochem Pharmacol</source><volume>56</volume><fpage>1493</fpage><lpage>1496</lpage><pub-id pub-id-type="pmid">9827583</pub-id></mixed-citation></ref><ref id="pone.0007540-Han1"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>JM</given-names></name><name><surname>Lee</surname><given-names>YJ</given-names></name><name><surname>Lee</surname><given-names>SY</given-names></name><name><surname>Kim</surname><given-names>EM</given-names></name><name><surname>Moon</surname><given-names>Y</given-names></name><etal/></person-group><year>2007</year><article-title>Protective effect of sulforaphane against dopaminergic cell death.</article-title><source>J Pharmacol Exp Ther</source><volume>321</volume><fpage>249</fpage><lpage>256</lpage><pub-id pub-id-type="pmid">17259450</pub-id></mixed-citation></ref><ref id="pone.0007540-Aleksunes1"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aleksunes</surname><given-names>LM</given-names></name><name><surname>Slitt</surname><given-names>AL</given-names></name><name><surname>Maher</surname><given-names>JM</given-names></name><name><surname>Dieter</surname><given-names>MZ</given-names></name><name><surname>Knight</surname><given-names>TR</given-names></name><etal/></person-group><year>2006</year><article-title>Nuclear factor-E2-related factor 2 expression in liver is critical for induction of NAD(P)H:quinone oxidoreductase 1 during cholestasis.</article-title><source>Cell Stress Chaperones</source><volume>11</volume><fpage>356</fpage><lpage>363</lpage><pub-id pub-id-type="pmid">17278884</pub-id></mixed-citation></ref><ref id="pone.0007540-Joung1"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joung</surname><given-names>EJ</given-names></name><name><surname>Li</surname><given-names>MH</given-names></name><name><surname>Lee</surname><given-names>HG</given-names></name><name><surname>Somparn</surname><given-names>N</given-names></name><name><surname>Jung</surname><given-names>YS</given-names></name><etal/></person-group><year>2007</year><article-title>Capsaicin induces heme oxygenase-1 expression in HepG2 cells via activation of PI3K-Nrf2 signaling: NAD(P)H:quinone oxidoreductase as a potential target.</article-title><source>Antioxid Redox Signal</source><volume>9</volume><fpage>2087</fpage><lpage>2098</lpage><pub-id pub-id-type="pmid">17979524</pub-id></mixed-citation></ref><ref id="pone.0007540-Siarey1"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siarey</surname><given-names>RJ</given-names></name><name><surname>Kline-Burgess</surname><given-names>A</given-names></name><name><surname>Cho</surname><given-names>M</given-names></name><name><surname>Balbo</surname><given-names>A</given-names></name><name><surname>Best</surname><given-names>TK</given-names></name><etal/></person-group><year>2006</year><article-title>Altered signaling pathways underlying abnormal hippocampal synaptic plasticity in the Ts65Dn mouse model of Down syndrome.</article-title><source>J Neurochem</source><volume>98</volume><fpage>1266</fpage><lpage>1277</lpage><pub-id pub-id-type="pmid">16895585</pub-id></mixed-citation></ref><ref id="pone.0007540-Smith2"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>DJ</given-names></name><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Cheng</surname><given-names>JF</given-names></name><name><surname>Rubin</surname><given-names>EM</given-names></name></person-group><year>1995</year><article-title>Construction of a panel of transgenic mice containing a contiguous 2-Mb set of YAC/P1 clones from human chromosome 21q22.2.</article-title><source>Genomics</source><volume>27</volume><fpage>425</fpage><lpage>434</lpage><pub-id pub-id-type="pmid">7558023</pub-id></mixed-citation></ref><ref id="pone.0007540-Reeves1"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reeves</surname><given-names>RH</given-names></name><name><surname>Irving</surname><given-names>NG</given-names></name><name><surname>Moran</surname><given-names>TH</given-names></name><name><surname>Wohn</surname><given-names>A</given-names></name><name><surname>Kitt</surname><given-names>C</given-names></name><etal/></person-group><year>1995</year><article-title>A mouse model for Down syndrome exhibits learning and behaviour deficits.</article-title><source>Nat Genet</source><volume>11</volume><fpage>177</fpage><lpage>184</lpage><pub-id pub-id-type="pmid">7550346</pub-id></mixed-citation></ref><ref id="pone.0007540-Fortin1"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fortin</surname><given-names>LJ</given-names></name><name><surname>Genest</surname><given-names>J</given-names></name></person-group><year>1995</year><article-title>Measurement of homocyst(e)ine in the prediction of atherosclerosis.</article-title><source>Clin Biochem</source><volume>28</volume><fpage>155</fpage><lpage>162</lpage><pub-id pub-id-type="pmid">7628074</pub-id></mixed-citation></ref><ref id="pone.0007540-Ducros1"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ducros</surname><given-names>V</given-names></name><name><surname>Demuth</surname><given-names>K</given-names></name><name><surname>Sauvant</surname><given-names>MP</given-names></name><name><surname>Quillard</surname><given-names>M</given-names></name><name><surname>Causs&#x000e9;</surname><given-names>E</given-names></name><etal/></person-group><year>2002</year><article-title>Methods for homocysteine analysis and biological relevance of the results.</article-title><source>J Chromatogr B Analyt Technol Biomed Life Sci</source><volume>781</volume><fpage>207</fpage><lpage>226</lpage></mixed-citation></ref><ref id="pone.0007540-Gellekink1"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gellekink</surname><given-names>H</given-names></name><name><surname>van Oppenraaij-Emmerzaal</surname><given-names>D</given-names></name><name><surname>van Rooij</surname><given-names>A</given-names></name><name><surname>Struys</surname><given-names>EA</given-names></name><name><surname>den Heijer</surname><given-names>M</given-names></name><etal/></person-group><year>2005</year><article-title>Stable-isotope dilution liquid chromatography-electrospray injection tandem mass spectrometry method for fast, selective measurement of S-adenosylmethionine and S-adenosylhomocysteine in plasma.</article-title><source>Clin Chem</source><volume>51</volume><fpage>1487</fpage><lpage>1492</lpage><pub-id pub-id-type="pmid">15919880</pub-id></mixed-citation></ref><ref id="pone.0007540-Miller1"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>JW</given-names></name><name><surname>Nadeau</surname><given-names>MR</given-names></name><name><surname>Smith</surname><given-names>D</given-names></name><name><surname>Selhub</surname><given-names>J</given-names></name></person-group><year>1994</year><article-title>Folate-deficiency-induced homocysteinaemia in rats: disruption of S-adenosylmethionine's co-ordinate regulation of homocysteine metabolism.</article-title><source>Biochem J</source><volume>298</volume><fpage>415</fpage><lpage>419</lpage><pub-id pub-id-type="pmid">8135750</pub-id></mixed-citation></ref><ref id="pone.0007540-Villanueva1"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Villanueva</surname><given-names>JA</given-names></name><name><surname>Halsted</surname><given-names>CH</given-names></name></person-group><year>2004</year><article-title>Hepatic transmethylation reactions in micropigs with alcoholic liver disease.</article-title><source>Hepatology</source><volume>39</volume><fpage>1303</fpage><lpage>1310</lpage><pub-id pub-id-type="pmid">15122759</pub-id></mixed-citation></ref><ref id="pone.0007540-Ernster1"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ernster</surname><given-names>L</given-names></name></person-group><year>1967</year><article-title>Methods Enzymol</article-title><volume>10</volume><fpage>309</fpage><lpage>317</lpage></mixed-citation></ref><ref id="pone.0007540-Benson1"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benson</surname><given-names>AM</given-names></name><name><surname>Hunkeler</surname><given-names>MJ</given-names></name><name><surname>Talalay</surname><given-names>P</given-names></name></person-group><year>1980</year><article-title>Increase of NAD(P)H:quinone reductase by dietary antioxidants: possible role in protection against carcinogenesis and toxicity.</article-title><source>Proc Natl Acad Sci U S A</source><volume>77</volume><fpage>5216</fpage><lpage>5220</lpage><pub-id pub-id-type="pmid">6933553</pub-id></mixed-citation></ref><ref id="pone.0007540-Tichopad1"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tichopad</surname><given-names>A</given-names></name><name><surname>Dilger</surname><given-names>M</given-names></name><name><surname>Schwarz</surname><given-names>G</given-names></name><name><surname>Pfaffl</surname><given-names>MW</given-names></name></person-group><year>2003</year><article-title>Standardized determination of real-time PCR efficiency from a single reaction set-up.</article-title><source>Nucleic Acids Res</source><volume>31</volume><fpage>e122</fpage><pub-id pub-id-type="pmid">14530455</pub-id></mixed-citation></ref></ref-list><fn-group><fn fn-type="conflict"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><fn fn-type="financial-disclosure"><p><bold>Funding: </bold>This work was supported by an EU grant AnEUploidy and by the Fondation Jerome Lejeune. Christophe Noll and Faycal Guedj are supported by a fellowship from the Ministere de l'Enseignement superieur et de la Recherche. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</p></fn></fn-group></back></article>